Diaryldiazepine Prodrugs for the Treatment of Neurological and Psychological Disorders

a diaryldiazepine and drug technology, applied in the field of diaryldiazepine drug prodrugs, can solve the problems of unreliable control of the degradation process required for the release of active agents, not all of these drugs have pharmacokinetic properties, and complicate dosage reproducibility, so as to reduce the solubility and polarity of the prodrug compound. , the effect of prolonging the action

Inactive Publication Date: 2011-07-07
ALKERMES INC
View PDF10 Cites 49 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention provides new ways to make certain types of medication more effective or faster-acting over time. By adding a long acting medicine called diphenyleneglyzesenepiperidine (DPEN) to the original drug, it becomes less soluble and easier to administer. This method can be used with different forms of the same type of medicine.

Problems solved by technology

The technical problem addressed in this patent text relates to improving the effectiveness of medications delivered via slow release compositions, particularly those containing anti-psychotic drugs like lithium hydroxypropyl nicotinate (LNP) and its analogues. Current methods involve either prolonged release or delayed release, but they cannot achieve sustainment without compromising efficacy. Therefore, there is a need for new ways to administer these types of drugs more effectively while maintaining their desired effects.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Diaryldiazepine Prodrugs for the Treatment of Neurological and Psychological Disorders
  • Diaryldiazepine Prodrugs for the Treatment of Neurological and Psychological Disorders
  • Diaryldiazepine Prodrugs for the Treatment of Neurological and Psychological Disorders

Examples

Experimental program
Comparison scheme
Effect test

example 1

1-methyl-4-(2-methyl-10H-benzo[b]thieno[2,3-e][1,4]diazepin-4-yl)-1-((stearoyloxy)methyl)piperazin-1-ium iodide (Compound 1)

A. Formation of Acid Chloride

[0133]To a stirred suspension of stearic acid (20 g, 70.3 mmol) in dichloromethane (100 mL) was added oxalyl chloride (8.92 mL, 105.5 mmol). 1 drop dimethylformamide was added and the reaction stirred at room temperature for 3 hours. The solvent was removed in vacuo and the resulting product used in the next step without further purification.

[0134]1H-NMR (CDCl3) δ 2.87 (t, 2H), 1.65-1.70 (m, 2H), 1.20-1.40 (m, 28H), 0.87 (3H, t).

B. Formation of Chloromethyl Alkyl Ester

[0135]Paraformaldehyde (2.11 g, 70.3 mmol) and zinc chloride (258 mg) were added to the acid chloride prepared above and the reaction mixture was heated at 65° C. for 16 hours and then allowed to cool to room temperature. Dichloromethane (200 mL) and saturated aqueous NaHCO3 (70 mL) were added. The aqueous emulsion was extracted with dichloromethane (2×50 mL) and the comb

example 2

1-methyl-4-(2-methyl-10H-benzo[b]thieno[2,3-e][1,4]diazepin-4-yl)-1-((palmitoyloxy)methyl)piperazin-1-ium iodide (Compound 2)

[0142]This compound was synthesized employing palmitoyl chloride. The product precipitated from the reaction mixture to give Compound 2 (1.23 g, endotherm peak in the DSC at 164° C.).

[0143]1H-NMR (CDCl3) δ 7.02-6.89 (3H, m), 6.67 (1H, dd), 6.35 (1H, s), 5.83 (2H, s), 5.32 (1H, s), 4.03-3.96 (2H, m), 3.79-3.71 (6H, m), 3.56 (3H, s), 2.52 (2H, t), 2.31 (3H, s), 1.64 (2H, t), 1.39-1.21 (24H, m), 0.87 (3H, t).

example 3

1-((butyryloxy)methyl)-1-methyl-4-(2-methyl-10H-benzo[b]thieno[2,3-e][1,4]diazepin-4-yl)piperazin-1-ium iodide (Compound 3)

[0144]This compound was synthesized employing butyryl chloride instead of stearyl chloride. The final precipitated from the reaction mixture to give Compound 3 (1.8 g, endotherm peak in the DSC at 203.2° C.).

[0145]1H-NMR (d6-DMSO) δ 6.77-6.88 (m, 3H), 6.65-6.69 (m, 1H), 6.37 (s, 1H), 5.42 (s, 2H), 3.78-3.89 (m, 2H), 3.45-3.60 (m, 6H), 3.16 (s, 3H), 2.51 (t, 2H), 2.25 (s, 3H), 1.57 (st, 2H), 0.89 (t, 3H).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Volumeaaaaaaaaaa
Volumeaaaaaaaaaa
Volumeaaaaaaaaaa
Login to view more

Abstract

The present invention provides prodrug compounds of diaryldiazepine drug compounds.

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Owner ALKERMES INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products